To assess the association of clinically used breast cancer markers with long-term survival and treatment benefit among postmenopausal women with lymph node–negative, estrogen receptor [ER]–positive and ERBB2-negative breast cancer who received tamoxifen therapy. Here, ERBB2 is linked to breast cancer.